Historical record - last NADAC effective date: 12/17/2014
Product Information
ZIAGEN 20 MG/ML SOLUTION is a brand product labeled by ViiV Healthcare Company, priced at $0.5865 per ML under NDC 49702022248. Its NADAC has been published 53 times since Dec 17, 2014.
FDA first approved this application on Dec 17, 1998. Its Orange Book therapeutic-equivalence code is AA.
Strength
20 mg/mL
Manufacturer
ViiV Healthcare CompanyNDC
49702022248
Classification
Brand
Dosage Form
SOLUTION
Route
ORAL
Effective Date
12/17/2014
Active Ingredients
ABACAVIR SULFATEApproval Type
New Drug (NDA)
FDA Application
NDA020978FDA Approved
12/17/1998
TE Code
AA
On Market Since
1/28/1999
Pharmacological Classes
Price Statistics
The NADAC for ZIAGEN 20 MG/ML SOLUTION has been published 53 times since Dec 17, 2014, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5865 per ML |
|---|---|
| All-time high | $0.5865 (Dec 16, 2015) |
| All-time low | $0.5865 (Dec 17, 2014) |
| Median price | $0.5865 |
| Average price | $0.5865 |
| Largest weekly change | 0.0% (Dec 24, 2014) |
| Weeks tracked | 53 |
| Tracking since | Dec 17, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
0.0%
Last surveyed Dec 16, 2015 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the abacavir sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ViiV Healthcare Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
abacavir sulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZIAGEN 20 MG/ML SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for ZIAGEN 20 MG/ML SOLUTION, manufactured by ViiV Healthcare Company, is $0.5865 per ML (NDC 49702022248), effective Dec 16, 2015.
How has the price of ZIAGEN 20 MG/ML SOLUTION changed over time?
Over the history we have for it, the NADAC for ZIAGEN 20 MG/ML SOLUTION has held within roughly two percent of its current level. It has been tracked across 53 weekly CMS publications since Dec 17, 2014.
What are the highest and lowest recorded NADAC prices for ZIAGEN 20 MG/ML SOLUTION?
Since Dec 17, 2014, the NADAC for ZIAGEN 20 MG/ML SOLUTION has ranged from a low of $0.5865 (Dec 17, 2014) to a high of $0.5865 (Dec 16, 2015), with a median of $0.5865 per ML.
Are there cheaper alternatives to ZIAGEN 20 MG/ML SOLUTION?
No other NADAC-published product currently shares the active ingredient and strength of ZIAGEN 20 MG/ML SOLUTION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZIAGEN 20 MG/ML SOLUTION?
ZIAGEN 20 MG/ML SOLUTION (NDC 49702022248) is labeled by ViiV Healthcare Company, and CMS classifies it as a brand product.